3T多参数前列腺MRI的PI-RADS v2评分可预测活检Gleason 3+4前列腺癌的肿瘤学结局
本研究回顾326例接受机器人根治性前列腺切除术、术前活检Gleason评分6-7分的患者,主要分析活检Gleason 3+4分者。发现PI-RADS v2 5分病变独立预测不良病理特征(多因素OR 11.4, 95%CI 3.7-35)和生化复发无生存,提示术前3T多参数MRI可作为独立于活检Gleason评分或活检类型的预后标志物。
要点
- 活检Gleason 3+4分患者中,PI-RADS v2 5分病变与不良病理特征独立相关(多因素OR 11.4, 95%CI 3.7-35)。
- 活检Gleason 3+4分且PI-RADS v2 5分者2年生化复发无生存率为58%,4分者为92%。
- 术前3T多参数MRI的PI-RADS v2评分可能作为独立于活检Gleason评分或活检类型的预后标志物。
核心结论
- 活检Gleason 3+4分患者中,PI-RADS v2 5分病变预测不良病理特征和生化复发无生存。
- 术前3T多参数MRI可能作为独立于活检Gleason评分或活检类型的治疗结局预后标志物。
研究设计与样本
- 回顾性分析326例连续接受机器人根治性前列腺切除术、术前模板和/或MRI-超声融合活检Gleason评分6-7分的前瞻性维护数据库患者记录。
- 主要分析在活检Gleason 3+4分患者中进行,采用单因素和多因素logistic回归评估不良病理特征,Kaplan-Meier法评估生化复发无生存。
- 对活检Gleason 6-7分患者进行类似分析。
主要发现
- 活检Gleason 3+4分患者中,PI-RADS v2评分0-2、3、4、5分分别占27%、15%、36%、23%。
- 单因素分析中,PI-RADS v2 5分 vs 0-2分预测不良病理特征(OR 10.7, 95%CI 3.7-31, p≤0.001)。
- 多因素分析调整术前MRI靶向活检后,PI-RADS v2 5分与不良病理相关(OR 11.4, 95%CI 3.7-35, p≤0.0001)。
- 靶向活检Gleason 3+4分患者中,PI-RADS v2 5分与不良病理相关(OR 14.7, 95%CI 1.5-146.9, p=0.02)。
- 活检Gleason 3+4分患者中,PI-RADS v2 4分和5分者2年生化复发无生存率分别为92%和58%。
临床怎么用
- 对于活检Gleason 3+4分前列腺癌患者,术前3T多参数MRI的PI-RADS v2评分可用于风险评估,5分病变提示不良病理和生化复发风险较高。
- PI-RADS v2评分可能辅助治疗决策,独立于活检Gleason评分或活检类型。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Three Tesla multiparametric magnetic resonance imaging with PI-RADS™ (Prostate Imaging Reporting and Data System) version 2 scoring is a common tool in prostate cancer diagnosis which informs the likelihood of a cancerous lesion. We investigated whether PI-RADS version 2 also predicts adverse pathology features mainly in patients with biopsy Gleason score 3 + 4 disease. MATERIALS AND METHODS: We reviewed the records of 326 consecutive men with a preoperative template and/or magnetic resonance imaging-ultrasound fusion biopsy Gleason score of 6-7 from a prospectively maintained database of men who underwent robotic radical prostatectomy. The primary analysis was done in patients with biopsy Gleason score 3 + 4 to assess the primary outcome of adverse pathology features on univariate and multivariate logistic regression. The secondary outcome was biochemical recurrence-free survival using the Kaplan-Meier method. Similar analysis was done in patients with a biopsy Gleason score of 6-7. RESULTS: Of men with Gleason score 3 + 4 findings 27%, 15%, 36% and 23% showed a PI-RADS version 2 score of 0-2, 3, 4 and 5, respectively. On univariate analysis PI-RADS version 2 category 5 predicted adverse pathology features vs categories 0-2 (OR 10.7, 95% CI 3.7-31, p ≤0.001). On multivariate analysis the PI-RADS version 2 category 5 was associated with adverse pathology when adjusting for preoperative magnetic resonance imaging targeted biopsy (OR 11.4, 95% CI 3.7-35, p ≤0.0001). In men with a targeted biopsy Gleason score of 3 + 4 prostate cancer PI-RADS version 2 category 5 was associated with adverse pathology (OR 14.7, 95% CI 1.5-146.9, p = 0.02). Of men with biopsy Gleason score 3 + 4 disease 92% and 58% with a PI-RADS version 2 score of 4 and 5, respectively, had 2-year biochemical recurrence-free survival. CONCLUSIONS: A PI-RADS version 2 category 5 lesion in patients with a biopsy Gleason score 3 + 4 lesion predicted adverse pathology features and biochemical recurrence-free survival. These findings suggest that preoperative 3 Tesla multiparametric magnetic resonance imaging may serve as a prognostic marker of treatment outcomes independently of biopsy Gleason score or biopsy type.
引用
- Faiena I, Salmasi A, Mendhiratta N, et al. PI-RADS Version 2 Category on 3 Tesla Multiparametric Prostate Magnetic Resonance Imaging Predicts Oncologic Outcomes in Gleason 3 + 4 Prostate Cancer on Biopsy. J Urol. 2019. PMID: 30577397. doi:10.1016/j.juro.2018.08.043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。